METTL3-mediated m6A modification of LINC00839 maintains glioma stem cells and radiation resistance by activating Wnt/β-catenin signaling

[1]  Monika Bansal,et al.  Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing , 2022, Pharmaceuticals.

[2]  Stephen T C Wong,et al.  Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer , 2022, Cancers.

[3]  I. Ulitsky,et al.  Substoichiometric action of long noncoding RNAs , 2022, Nature Cell Biology.

[4]  Jae-Bong Park,et al.  Cross-Talk between Wnt Signaling and Src Tyrosine Kinase , 2022, Biomedicines.

[5]  Xinghuo Wu,et al.  WTAP-mediated m6A modification of lncRNA NORAD promotes intervertebral disc degeneration , 2022, Nature Communications.

[6]  Xinjian Li,et al.  Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma. , 2022, Molecular cell.

[7]  H. Daldrup-Link,et al.  Glioblastoma Multiforme (GBM): An overview of current therapies and mechanisms of resistance. , 2021, Pharmacological research.

[8]  Wenqi Wang,et al.  A phosphatidic acid-binding lncRNA SNHG9 facilitates LATS1 liquid–liquid phase separation to promote oncogenic YAP signaling , 2021, Cell Research.

[9]  Jennifer S. Yu,et al.  Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice , 2021, Science Translational Medicine.

[10]  Xiao Feng,et al.  N-methyladenosine reader YTHDF2-mediated long noncoding RNA FENDRR degradation promotes cell proliferation in endometrioid endometrial carcinoma , 2021, Laboratory Investigation.

[11]  Li Ma,et al.  EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma , 2021, Nature communications.

[12]  Y. You,et al.  Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p , 2021, Theranostics.

[13]  Gui-Chen Li,et al.  Long non-coding RNAs as epigenetic mediators of glioma progression and metastasis: Running Title: lncRNAs in glioma progression. , 2020, Seminars in cancer biology.

[14]  H. Friedman,et al.  Management of glioblastoma: State of the art and future directions. , 2020, CA: a cancer journal for clinicians.

[15]  A. Giuliani,et al.  Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3 , 2020, Neuro-oncology.

[16]  Y. You,et al.  DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma , 2020, Molecular Cancer.

[17]  R. Bjerkvig,et al.  Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/β-catenin signalling , 2019, Brain : a journal of neurology.

[18]  Yanxin Li,et al.  TGF‐β‐activated lncRNA LINC00115 is a critical regulator of glioma stem‐like cell tumorigenicity , 2019, EMBO reports.

[19]  Gang Yin,et al.  Functions of N6-methyladenosine and its role in cancer , 2019, Molecular Cancer.

[20]  Ok Hyun Park,et al.  Endoribonucleolytic Cleavage of m6A-Containing RNAs by RNase P/MRP Complex. , 2019, Molecular cell.

[21]  G. Reifenberger,et al.  The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells , 2019, Cell Death & Disease.

[22]  Lennart Martens,et al.  LNCipedia 5: towards a reference set of human long non-coding RNAs , 2018, Nucleic Acids Res..

[23]  Jennifer S. Yu,et al.  Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance , 2018, Science Translational Medicine.

[24]  Andrew R. Morton,et al.  Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression. , 2018, Cell stem cell.

[25]  Chao Xu,et al.  YTH Domain: A Family of N6-methyladenosine (m6A) Readers , 2018, Genom. Proteom. Bioinform..

[26]  K. Somasundaram,et al.  Essential role of METTL3-mediated m6A modification in glioma stem-like cells maintenance and radioresistance , 2018, Oncogene.

[27]  Stepanka Vanacova,et al.  N6-methyladenosine demethylase FTO targets pre-mRNAs and regulates alternative splicing and 3′-end processing , 2017, Nucleic acids research.

[28]  Tao Pan,et al.  Dynamic RNA Modifications in Gene Expression Regulation , 2017, Cell.

[29]  Chuan He,et al.  m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. , 2017, Cancer cell.

[30]  Q. Cui,et al.  SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features , 2016, Nucleic acids research.

[31]  Jian Hu,et al.  Glioma Stem Cells: Signaling, Microenvironment, and Therapy , 2016, Stem cells international.

[32]  Howard Y. Chang,et al.  Unique features of long non-coding RNA biogenesis and function , 2015, Nature Reviews Genetics.

[33]  M. Kool,et al.  Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance , 2015, Nature Communications.

[34]  Jing Hu,et al.  Regulation of Wnt/β-catenin signaling by posttranslational modifications , 2014, Cell & Bioscience.

[35]  Donald J Buchsbaum,et al.  The Wnt/β-catenin pathway in ovarian cancer: a review. , 2013, Gynecologic oncology.

[36]  Zhike Lu,et al.  m6A-dependent regulation of messenger RNA stability , 2013, Nature.

[37]  Atique U. Ahmed,et al.  Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies , 2013, Expert review of neurotherapeutics.

[38]  R. McLendon,et al.  Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth , 2013, Cell.

[39]  S. Krauss,et al.  Wnt/beta-Catenin Signaling and Small Molecule Inhibitors , 2012, Current pharmaceutical design.

[40]  R. McLendon,et al.  Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. , 2011, Cancer cell.

[41]  A. Friedman,et al.  Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma , 2005, Cancer.

[42]  S. Parsons,et al.  Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor and c-Src interactions in breast cancer , 2000, Breast Cancer Research.

[43]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.